AstraZeneca investors revolt on pay as mega-mergers near
The pharmaceuticals giant AstraZeneca was rocked by a shareholder rebellion yesterday when almost 40 per cent of its investors failed to back executive pay at the group.
The company, which is a $100bn (£60bn) takeover target for US rival Pfizer, suffered the setback at its annual meeting, where just 60.6 per cent of shareholders approved its remuneration report, which resulted in the chief executive, Pascal Soriot, taking home more than £3.3m in pay and bonuses last year.
The rebellion came after Mr Soriot announced the possible sale or spin-off of non-core businesses in a move that analysts said could be worth up to $15bn. However, he remained tight-lipped about the possibility of Pfizer making a formal bid for AstraZeneca following news of informal discussions late last year. “We have a firm policy on not commenting on things like this and that has not changed,” he said. “We prefer to talk about things we are doing to grow the business.”
Mr Soriot said AstraZeneca was considering options similar to the asset swap between Novartis and GlaxoSmithKline earlier this week, in which the companies exchanged non-core units and formed a joint venture in consumer healthcare. He also highlighted success in new cancer drugs, taken to late-stage clinical trials, including treatments for lung cancer and ovarian cancer. AstraZeneca’s sales in the three months to March were flat at $6.42bn (£5.28bn).
The pharmaceuticals and healthcare sector has been a hive of mergers and acquisitions in recent weeks. This intensified further yesterday when Zimmer Holdings, the US maker of medical devices, agreed to buy rival Biomet in a deal worth $13.4bn (£7.9bn).
Analysts at Bernstein said Zimmer’s deal with Indiana-based Biomet could be a prelude to further consolidation in the medical equipment sector, speculating that British-based hip-joint maker Smith & Nephew could be a target for Johnson and Johnson of the US. Shares in Smith & Nephew, which rejected a £15bn merger with Biomet in 2011, jumped sharply.
The Zimmer-Biomet merger, which would create America’s eighth-largest medical devices company by sales, is expected to close in the first quarter of 2015.
Zimmer said that the tie-up would improve its offering in knee, hip, surgical, spine and dental products and result in $270m of synergies over three years.
- 1 This 'woman calls police to order pizza' story isn't going where you're expecting
- 2 Axe wielding man shot dead after attacking four New York policemen on busy street
- 3 Watch what happened when food critics were unknowingly served McDonald's
- 4 Jimmy Carr's Oscar Pistorius joke goes a bit too far at the Q Awards
- 5 Ottawa shootings: Bruce MacKinnon's cartoon is the perfect tribute to soldier Nathan Cirillo
Renee Zellweger on plastic surgery rumours: 'I'm living a more fulfilling life and I'm thrilled that perhaps it shows'
FCKH8: YouTube reinstates provocative anti-sexism video showing young girls swearing
Axe wielding man shot dead after attacking four New York policemen on busy street
This 'woman calls police to order pizza' story isn't going where you're expecting
McKamey Manor: This 'extreme' haunted house is the stuff of nightmares
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Attacks on 'Ukip Calypso' show how skewed people’s priorities are
Poppy Appeal 2014: This is why I won't be wearing a red poppy this year
iJobs Money & Business
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...
£30000 - £35000 Per Annum plus excellent benefits: Clearwater People Solutions...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...